Traduction de «first pa-european » (Néerlandais → Français) :

TERMINOLOGIE

first-pass | eerste hindernis
?

TRADUCTIONS EN CONTEXTE

Lepine JP, Gastpar, Mendlecicz J, Tylee A. Depression in the community : the first pa-European study DEPRES (Depression Research in European Society).
Lepine JP, Gastpar, Mendlecicz J, Tylee A. Depression in the community: the first pa-European study DEPRES (Depression Research in European Society).

Tabel 5. Belangrijkste conferenties over de gezondheid van artsen Jaar Titel van de Conferentie Organisator 1996 First European research conference on physicians ‘health NMA 2001 First European Meeting PAIMM PAIMM 2004 International Conference on Physician Health: Creating a healthy culture CMA in medicine 2008 Doctor’s health matters: finding the balance AMA CMA BMA
Tableau 5. Principales conférences organisées sur le thème de la santé des médecins Année Titre de la Conférence Organisateur 1996 First European research conference on physicians ‘health NMA 2001 First European Meeting PAIMM PAIMM 2004 International Conference on Physician Health: Creating a healthy CMA culture in medicine 2008 Doctor’s health matters : finding the balance AMA CMA BMA

Compliance with the European directives on electronic submissions Compliance with the European directives requires a number of objectives to be achieved: ●● Arriving at a functional vision of communication standards with EMEA and the Member States in partnership with the industry and in line with European legislation ●● Standard project management, with important steps that are sponsored/supported by the Member States: first developing an IT infrastructure and then starting on a highly secure network followed by so-called “proofs of concept” in each field ●● Success depends above all on the FAHMP’s
Compliance with the European directives on electronic submissions Compliance with the European directives requires a number of objectives to be achieved: ●● Arriving at a functional vision of communication standards with EMEA and the Member States in partnership with the industry and in line with European legislation ●● Standard project management, with important steps that are sponsored/supported by the Member States: first developing an IT infrastructure and then starting on a highly secure network followed by so-called “proofs of concept” in each field ●● Success depends above all on the FAHMP’s

On a European level, the Scientific Committee on Food (SCF) issued a first opinion on caffeine, taurine and D-glucuronolactone as ingredients of energy drinks in 1999 (SCF, 1999).
Au niveau européen, le Scientific Committee on Food (SCF) a rendu en 1999 un premier avis concernant la caféine, la taurine et le D-glucuronolactone comme constituants des boissons énergisantes (SCF, 1999).

The key elements of this ambition are, firstly, the provision of efficient and high-quality services and, secondly, compliance with all the legal requirements imposed on the FAMHP (taking account of the revised Belgian pharmaceutical legislation and the European Directives).
The key elements of this ambition are, firstly, the provision of efficient and high-quality services and, secondly, compliance with all the legal requirements imposed on the FAMHP (taking account of the revised Belgian pharmaceutical legislation and the European Directives).

Extavia (USD 26 million), for patients with relapsing forms of multiple sclerosis (MS), was first launched in the European Union in early 2009 and is now available in more than 15 countries, including the US where it was launched recently after regulatory approval was granted in August 2009.
Extavia (USD 26 millions), pour les malades atteints de formes cycliques de sclérose en plaques (SEP), a été commercialisé d’abord dans l’Union européenne début 2009.

Galvus/Eucreas (USD 181 million, +327% lc), oral treatments for type 2 diabetes, have achieved rapid success in many European, Latin American and Asia-Pacific markets since first launched in 2007.
Galvus/Eucreas (USD 181 millions, +327% en m. l.), traitements par voie orale du diabète de type 2, ont très vite rencontré le succès dans de nombreux marchés d'Europe, d'Amérique latine et d'Asie-Pacifique depuis leur premier lancement en 2007.

European approval is expected in early 2010 after a positive opinion in December 2009, while a US regulatory decision is also expected in the first half of the year.
En Europe, une autorisation devrait être délivrée début 2010, après un avis favorable émis en décembre 2009, tandis qu’une décision est également attendue au premier semestre aux Etats-Unis.

In addition, “Customers First” was launched in February 2010 after pilot programs to accelerate collaboration across the businesses in 45 countries – including the US, top European markets and Japan – that together represent 95% of Group net sales.
De surcroît, le projet «Customers First» a été lancé en février 2010, après des programmes pilotes, afin d’accélérer la collaboration entre divisions dans 45 pays, notamment aux Etats-Unis, dans les principaux marchés européens et au Japon, qui ensemble représentent 95% du chiffre d’affaires net du Groupe.

An industry leader in new product approvals, Novartis achieved US and European Union approvals in the first quarter for Menveo, a new vaccine offering protection against four major serogroups of meningococcal meningitis, a potentially fatal bacterial disease.
Parmi les leaders de l’industrie en ce qui concerne les autorisations pour de nouveaux produits, Novartis a obtenu, au premier trimestre 2010, l’homologation de Menveo aux Etats-Unis et dans l’Union européenne. Il s’agit d’un nouveau vaccin qui protège contre les quatre principaux sérogroupes de méningite à méningocoque, une maladie bactérienne potentiellement mortelle.